2076975 2077203
최종편집 2024-06-24 07:03 (월)
MFDS approves diffuse large B-cell lymphoma treatment Minjuvi 
상태바
MFDS approves diffuse large B-cell lymphoma treatment Minjuvi 
  • Hyeokgi Lee, Newsmp
  • 승인 2023.06.12 22:43
  • 댓글 0
이 기사를 공유합니다

Offering new treatment options for patients with rare blood cancer

[Newsmp] The Ministry of Food and Drug Safety authorized the use of the orphan medication 'Minjuvi (Tafasitamab)' for the treatment of diffuse large B-cell lymphoma on 9 June.

Diffuse large B-cell lymphoma is the most common lymphoma, known for its fast progression.

In the treatment of diffuse large B-cell lymphoma in adults, Minjuvi is used first in combination with lenalidomide and later its own.

And it is specifically intended for individuals whose cancer has returned or shown resistance to previous treatments and who are not eligible for autologous stem cell transplantation.

This medication provides new treatment opportunities for diffuse large B-cell lymphoma by attaching to the CD19 protein on B-cell surfaces, leading to direct cell death, antibody-dependent cellular phagocytosis, and antibody-dependent cellular cytotoxicity, resulting in B-cell depletion.

The Ministry of Food and Drug Safety described Minjuvi as a humanized CD19-specific monoclonal antibody of the immunoglobulin G (IgG), a cell surface antigen protein on B-lymphocytes.


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.